9 Results for "

RAF-IN-2

" in MedChemExpress (MCE) Product Catalog:
Products (9)

9 Results for "RAF-IN-2" in MCE Product Catalog:

Cat. No.: HY-177279
CAS No.: 258851-00-2
Target:  

Raf

Research Areas:  

Inflammation/Immunology Cancer

RAF-IN-2 is a RAF inhibitor. RAF-IN-2 can be used for proliferative diseases such as leukemia, psoriasis and fibrosis research .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-10248
CAS No.: 927880-90-8
Purity:  99.80%
Synonyms: CHIR-265
Research Areas:  

Cancer

RAF265 is a potent and orally active RAF/VEGFR2 inhibitor.
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-109574
CAS No.: 220904-99-4
Purity:  98.48%
Target:  

Raf

Research Areas:  

Cancer

Raf inhibitor 2 is a potent raf kinase (IC50<1.0 μM) inhibitor, compound 32, extracted from patent EP1003721B1. Raf inhibitor 2 can be used for cancer research .
loading...
    loading...
Cat. No.: HY-145120
CAS No.: 2649372-20-1
Purity:  98.29%
Synonyms: RG6344; RO7276389; B-RAF IN 2
Target:  

Raf

Research Areas:  

Cancer

BRAF inhibitor. RG6344 can be used for the study of BRAF V600-mutant solid tumors, such as colorectal cancer (CRC) .
loading...
    loading...
Cat. No.: HY-18832
CAS No.: 1135205-94-5
Target:  

Ephrin Receptor

Research Areas:  

Cancer

AWL-II-38.3 is a potent ephrin-A receptor (EphA3) kinase inhibitor. AWL-II-38.3 does not exhibit significant cellular activity against Src-family kinases nor against b-raf [2].
loading...
    loading...
Cat. No.: HY-114491
CAS No.: 1715025-32-3
Purity:  99.83%
Rineterkib (compound B) is an orally available ERK1 and ERK2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC, BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovarian cancer. Rineterkib hydrochloride can also inhibit RAF .
loading...
    loading...
Cat. No.: HY-51424S
CAS No.: 1304096-50-1
PLX-4720-d7 is the deuterium labeled PLX-4720. PLX-4720 is a potent and selective inhibitor of?B-RafV600E?with?an IC50?of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), and 10-fold selectivity for B-RafV600E than wild-type B-Raf .
loading...
    loading...
Cat. No.: HY-114491A
CAS No.: 1715025-34-5
Purity:  99.81%
Target:  

ERK Raf

Research Areas:  

Cancer

Rineterkib hydrochloride (compound B) is an orally available ERK1 and ERK2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC, BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovarian cancer. Rineterkib hydrochloride can also inhibit RAF .
loading...
    loading...
Cat. No.: HY-10248R
CAS No.: 927880-90-8
Synonyms: CHIR-265 (Standard)
Research Areas:  

Cancer

RAF265 (Standard) is the analytical standard of RAF265 (HY-10248). This product is intended for research and analytical applications. RAF265 is a potent and orally active RAF/VEGFR2 inhibitor.
loading...
    loading...